Synlogic, Inc.

SYBX Healthcare Biotechnology

Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.00 0.08 −7.41%
Market cap
$6.7M
P/E
0.0×
Fwd P/E
−2.8×
Dividend yield
—
F-score
3/9
Altman Z
−35.79
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.65 4.30 7.08 9.19
Net Debt/EBITDA
15.73 10.93 10.69 13.03
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.12) (0.07) (0.05) (0.07)
Book value per Share
0.84 0.96 1.01 0.97
Free Cash Flow
(1.44) (0.92) (0.56) (0.92)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates